Epigenetic therapy: azacytidine and decitabine in acute myeloid leukemia

References

• Döhner H, Weisdorf DJ, Bloomfield CD. Acute myeloid leukemia. N Engl J Med. 2015 Sep 17;373(12):1136–1152.
   PubMed Web of Science ®Google Scholar
• Krug U, Gale RP, Berdel WE, et al. Therapy of older persons with acute myeloid leukaemia. Leukemia Res. 2017;60:1–10.
   PubMed Web of Science ®Google Scholar
• Jones PA. Functions of DNA methylation: islands, start sites, gene bodies and beyond. Nat Rev Genet. 2012 May 29;13(7):484–492.
   PubMed Web of Science ®Google Scholar
• Esteller M. Epigenetics in cancer. N Engl J Med. 2008 Mar 13;358(11):1148–1159.
   PubMed Web of Science ®Google Scholar
• Hansen KD, Timp W, Bravo HC, et al. Increased methylation variation in epigenetic domains across cancer types. Nat Genet. 2011 Jun 26;43(8):768–775.
   PubMed Web of Science ®Google Scholar
• Timp W, Feinberg AP. Cancer as a dysregulated epigenome allowing cellular growth advantage at the expense of the host. Nat Rev Cancer. 2013 Jul;13(7):497–510.
   PubMed Web of Science ®Google Scholar
• Wouters BJ, Delwel R. Epigenetics and approaches to targeted epigenetic therapy in acute myeloid leukemia. Blood. 2016 Jan 07;127(1):42–52.
   PubMed Web of Science ®Google Scholar
• Figueroa ME, Lugthart S, Li Y, et al. DNA methylation signatures identify biologically distinct subtypes in acute myeloid leukemia. Cancer Cell. 2010 Jan 19;17(1):13–27.
   PubMed Web of Science ®Google Scholar
• Tj L, Miller C, Ding L, et al. Genomic and epigenomic landscapes of adult de novo acute myeloid leukemia. N Engl J Med. 2013 May 30;368(22):2059–2074.
   PubMed Web of Science ®Google Scholar
• Estey EH. Epigenetics in clinical practice: the examples of azacitidine and decitabine in myelodysplasia and acute myeloid leukemia. Leukemia. 2013 Sep;27(9):1803–1812.
   PubMed Web of Science ®Google Scholar
• Daskalakis M, Blagitko-Dorfs N, Hackanson B. Decitabine. Recent Results Cancer Res. 2010;184:131–157.
   Google Scholar
• Navada SC, Steinmann J, Lubbert M, et al. Clinical development of demethylating agents in hematology. J Clin Invest. 2014 Jan;124(1):40–46.
   PubMed Web of Science ®Google Scholar
• Yun S, Vincelette ND, Abraham I, et al. Targeting epigenetic pathways in acute myeloid leukemia and myelodysplastic syndrome: a systematic review of hypomethylating agents trials. Clin Epigenet. 2016;8:68.
   PubMed Web of Science ®Google Scholar
• Blum W, Garzon R, Klisovic RB, et al. Clinical response and miR-29b predictive significance in older AML patients treated with a 10-day schedule of decitabine. Proc Natl Acad Sci USA. 2010 Apr 20;107(16):7473–7478.
   PubMed Web of Science ®Google Scholar
• Shin DY, Park YS, Yang K, et al. Decitabine, a DNA methyltransferase inhibitor, induces apoptosis in human leukemia cells through intracellular reactive oxygen species generation. Int J Oncol. 2012 Sep;41(3):910–918.
   PubMed Web of Science ®Google Scholar
• Garzon R, Liu S, Fabbri M, et al. MicroRNA-29b induces global DNA hypomethylation and tumor suppressor gene reexpression in acute myeloid leukemia by targeting directly DNMT3A and 3B and indirectly DNMT1. Blood. 2009 Jun 18;113(25):6411–6418.
   PubMed Web of Science ®Google Scholar
• Voso MT, Santini V, Fabiani E, et al. Why methylation is not a marker predictive of response to hypomethylating agents. Haematologica. 2014 Apr;99(4):613–619.
   PubMed Web of Science ®Google Scholar
• Fenaux P, Mufti GJ, Hellstrom-Lindberg E, et al. Efficacy of azacitidine compared with that of conventional care regimens in the treatment of higher-risk myelodysplastic syndromes: a randomised, open-label, phase III study. Lancet Oncol. 2009 Mar;10(3):223–232.
   PubMed Web of Science ®Google Scholar
• Quintas-Cardama A, Ravandi F, Liu-Dumlao T, et al. Epigenetic therapy is associated with similar survival compared with intensive chemotherapy in older patients with newly diagnosed acute myeloid leukemia. Blood. 2012 Dec 6;120(24):4840–4845.
   PubMed Web of Science ®Google Scholar
• He PF, Zhou JD, Yao DM, et al. Efficacy and safety of decitabine in treatment of elderly patients with acute myeloid leukemia: a systematic review and meta-analysis. Oncotarget. 2017 Jun 20;8(25):41498–41507.
   PubMedGoogle Scholar
• Stresemann C, Brueckner B, Musch T, et al. Functional diversity of DNA methyltransferase inhibitors in human cancer cell lines. Cancer Res. 2006 Mar 1;66(5):2794–2800.
   PubMed Web of Science ®Google Scholar
• Garcia-Manero G, Gore SD, Cogle C, et al. Phase I study of oral azacitidine in myelodysplastic syndromes, chronic myelomonocytic leukemia, and acute myeloid leukemia. J Clin Oncol. 2011 Jun 20;29(18):2521–2527.
   PubMed Web of Science ®Google Scholar
• Zhang Y, Sun J, Gao Y, et al. A carrier-mediated prodrug approach to improve the oral absorption of antileukemic drug decitabine. Mol Pharm. 2013 Aug 5;10(8):3195–3202.
   PubMedGoogle Scholar
• Garcia-Manero G, Odenike O, Amrein PC, et al. Successful emulation of IV decitabine pharmacokinetics with an oral fixed-dose combination of the oral cytidine deaminase inhibitor (CDAi) E7727 with oral decitabine, in subjects with myelodysplastic syndromes (MDS): final data of phase 1 study. Blood. 2016;128(22):114–115.
   Web of Science ®Google Scholar
• Lubbert M, Ruter BH, Claus R, et al. A multicenter phase II trial of decitabine as first-line treatment for older patients with acute myeloid leukemia judged unfit for induction chemotherapy. Haematologica. 2012 Mar;97(3):393–401.
   PubMed Web of Science ®Google Scholar
• Metzeler KH, Walker A, Geyer S, et al. DNMT3A mutations and response to the hypomethylating agent decitabine in acute myeloid leukemia. Leukemia. 2012 May;26(5):1106–1107.
   PubMed Web of Science ®Google Scholar
• Steensma DP, Baer MR, Slack JL, et al. Multicenter study of decitabine administered daily for 5 days every 4 weeks to adults with myelodysplastic syndromes: the alternative dosing for outpatient treatment (ADOPT) trial. J Clin Oncol. 2009 Aug 10;27(23):3842–3848.
   PubMed Web of Science ®Google Scholar
• Welch JS, Petti AA, Miller CA, et al. TP53 and decitabine in acute myeloid leukemia and myelodysplastic syndromes. N Engl J Med. 2016 Nov 24;375(21):2023–2036.
   PubMed Web of Science ®Google Scholar
• Roboz GJ, Kantarjian HM. Dose, schedule, safety, and efficacy of guadecitabine in relapsed or refractory acute myeloid leukemia. Cancer. 2018 Jan 15;124(2):325–334.
   Google Scholar
• Qin T, Jelinek J, Si J, et al. Mechanisms of resistance to 5-aza-2ʹ-deoxycytidine in human cancer cell lines. Blood. 2009 Jan 15;113(3):659–667.
   PubMed Web of Science ®Google Scholar
• Pastor-Anglada M, Molina-Arcas M, Casado FJ, et al. Nucleoside transporters in chronic lymphocytic leukaemia. Leukemia. 2004 Mar;18(3):385–393.
   PubMed Web of Science ®Google Scholar
• Valencia A, Masala E, Rossi A, et al. Expression of nucleoside-metabolizing enzymes in myelodysplastic syndromes and modulation of response to azacitidine. Leukemia. 2014 Mar;28(3):621–628.
   PubMed Web of Science ®Google Scholar
• Diesch J, Zwick A, Garz AK, et al. A clinical-molecular update on azanucleoside-based therapy for the treatment of hematologic cancers. Clin Epigenet. 2016;8:71.
   PubMed Web of Science ®Google Scholar
• Palii SS, Van Emburgh BO, Sankpal UT, et al. DNA methylation inhibitor 5-Aza-2ʹ-deoxycytidine induces reversible genome-wide DNA damage that is distinctly influenced by DNA methyltransferases 1 and 3B. Mol Cell Biol. 2008 Jan;28(2):752–771.
   PubMed Web of Science ®Google Scholar
• Ghoshal K, Datta J, Majumder S, et al. 5-Aza-deoxycytidine induces selective degradation of DNA methyltransferase 1 by a proteasomal pathway that requires the KEN box, bromo-adjacent homology domain, and nuclear localization signal. Mol Cell Biol. 2005 Jun;25(11):4727–4741.
   PubMed Web of Science ®Google Scholar
• Hollenbach PW, Nguyen AN, Brady H, et al. A comparison of azacitidine and decitabine activities in acute myeloid leukemia cell lines. PloS One. 2010 Feb 2;5(2):e9001.
   PubMed Web of Science ®Google Scholar
• Aimiuwu J, Wang H, Chen P, et al. RNA-dependent inhibition of ribonucleotide reductase is a major pathway for 5-azacytidine activity in acute myeloid leukemia. Blood. 2012 May 31;119(22):5229–5238.
   PubMed Web of Science ®Google Scholar
• Jasielec J, Saloura V, Godley LA. The mechanistic role of DNA methylation in myeloid leukemogenesis. Leukemia. 2014 Sep;28(9):1765–1773.
   PubMed Web of Science ®Google Scholar
• Yan P, Frankhouser D, Murphy M, et al. Genome-wide methylation profiling in decitabine-treated patients with acute myeloid leukemia. Blood. 2012 Sep 20;120(12):2466–2474.
   PubMed Web of Science ®Google Scholar
• Karon M, Sieger L, Leimbrock S, et al. 5-Azacytidine: a new active agent for the treatment of acute leukemia. Blood. 1973 Sep;42(3):359–365.
   PubMed Web of Science ®Google Scholar
• Saiki JH, McCredie KB, Vietti TJ, et al. 5-azacytidine in acute leukemia. Cancer. 1978 Nov;42(5):2111–2114.
   PubMed Web of Science ®Google Scholar
• Harris NL, Jaffe ES, Diebold J, et al. World Health Organization classification of neoplastic diseases of the hematopoietic and lymphoid tissues: report of the Clinical Advisory Committee meeting-Airlie House, Virginia, November 1997. J Clin Oncol. 1999 Dec;17(12):3835–3849.
   PubMed Web of Science ®Google Scholar
• Silverman LR, McKenzie DR, Peterson BL, et al. Further analysis of trials with azacitidine in patients with myelodysplastic syndrome: studies 8421, 8921, and 9221 by the Cancer and Leukemia Group B. J Clin Oncol. 2006 Aug 20;24(24):3895–3903.
   PubMed Web of Science ®Google Scholar
• Fenaux P, Mufti GJ, Hellstrom-Lindberg E, et al. Azacitidine prolongs overall survival compared with conventional care regimens in elderly patients with low bone marrow blast count acute myeloid leukemia. J Clin Oncol. 2010 Feb 1;28(4):562–569.
   PubMed Web of Science ®Google Scholar
• Dombret H, Seymour JF, Butrym A, et al. International phase 3 study of azacitidine vs conventional care regimens in older patients with newly diagnosed AML with >30% blasts. Blood. 2015 Jul 16;126(3):291–299.
   PubMed Web of Science ®Google Scholar
• Garcia-Delgado R, de Miguel D, Bailen A, et al. Effectiveness and safety of different azacitidine dosage regimens in patients with myelodysplastic syndromes or acute myeloid leukemia. Leuk Res. 2014 Jul;38(7):744–750.
   PubMed Web of Science ®Google Scholar
• Huls G, Chitu D, Havelange V, et al. Randomized maintenance therapy with azacitidine (Vidaza) in older patients (≥60 years of age) with acute myeloid leukemia (AML) and refractory anemia with excess of blasts (RAEB, RAEB-t). Results of the HOVON97 phase III randomized multicentre study (EudraCT 2008-001290-15). Blood. 2017;130(Suppl1):463–464.
   Google Scholar
• Itzykson R, Thepot S, Berthon C, et al. Azacitidine for the treatment of relapsed and refractory AML in older patients. Leuk Res. 2015 Feb;39(2):124–130.
   PubMed Web of Science ®Google Scholar
• Pinto A, Attadia V, Fusco A, et al. 5-Aza-2ʹ-deoxycytidine induces terminal differentiation of leukemic blasts from patients with acute myeloid leukemias. Blood. 1984 Oct;64(4):922–929.
   PubMed Web of Science ®Google Scholar
• Pinto A, Zagonel V, Attadia V, et al. 5-Aza-2ʹ-deoxycytidine as a differentiation inducer in acute myeloid leukaemias and myelodysplastic syndromes of the elderly. Bone Marrow Transplant. 1989 Dec;4(Suppl 3):28–32.
   PubMed Web of Science ®Google Scholar
• Cashen AF, Shah AK, Todt L, et al. Pharmacokinetics of decitabine administered as a 3-h infusion to patients with acute myeloid leukemia (AML) or myelodysplastic syndrome (MDS). Cancer Chemother Pharmacol. 2008 Apr;61(5):759–766.
   PubMed Web of Science ®Google Scholar
• Cashen AF, Schiller GJ, O’Donnell MR, et al. Multicenter, phase II study of decitabine for the first-line treatment of older patients with acute myeloid leukemia. J Clin Oncol. 2010 Feb 1;28(4):556–561.
   PubMed Web of Science ®Google Scholar
• Kantarjian HM, Thomas XG, Dmoszynska A, et al. Multicenter, randomized, open-label, phase III trial of decitabine versus patient choice, with physician advice, of either supportive care or low-dose cytarabine for the treatment of older patients with newly diagnosed acute myeloid leukemia. J Clin Oncol. 2012 Jul 20;30(21):2670–2677.
   PubMed Web of Science ®Google Scholar
• Kadia TM, Thomas XG, Dmoszynska A, et al. Decitabine improves outcomes in older patients with acute myeloid leukemia and higher blast counts. Am J Hematol. 2015 Jul;90(7):E139–41.
   PubMed Web of Science ®Google Scholar
• Tawfik B, Sliesoraitis S, Lyerly S, et al. Efficacy of the hypomethylating agents as frontline, salvage, or consolidation therapy in adults with acute myeloid leukemia (AML). Ann Hematol. 2014 Jan;93(1):47–55.
   PubMed Web of Science ®Google Scholar
• Momparler RL. A perspective on the comparative antileukemic activity of 5-Aza-2ʹ-deoxycytidine (Decitabine) and 5-Azacytidine (Vidaza). Pharmaceuticals (Basel, Switzerland). 2012 Aug 21;5(8):875–881.
   PubMedGoogle Scholar
• Montalban-Bravo G, Takahashi K, Garcia-Manero G. Decitabine in TP53-mutated AML. N Engl J Med. 2017 Feb 23;376(8):796–797.
   PubMed Web of Science ®Google Scholar
• Derissen EJ, Beijnen JH, Schellens JH. Concise drug review: azacitidine and decitabine. Oncologist. 2013;18(5):619–624.
   PubMed Web of Science ®Google Scholar
• Ravandi F, Issa JP, Garcia-Manero G, et al. Superior outcome with hypomethylating therapy in patients with acute myeloid leukemia and high-risk myelodysplastic syndrome and chromosome 5 and 7 abnormalities. Cancer. 2009 Dec 15;115(24):5746–5751.
   PubMed Web of Science ®Google Scholar
• Jabbour E, Short NJ, Montalban-Bravo G, et al. Randomized phase 2 study of low-dose decitabine vs low-dose azacitidine in lower-risk MDS and MDS/MPN. Blood. 2017 Sep 28;130(13):1514–1522.
   PubMed Web of Science ®Google Scholar
• Cabrero M, Jabbour E, Ravandi F, et al. Discontinuation of hypomethylating agent therapy in patients with myelodysplastic syndromes or acute myelogenous leukemia in complete remission or partial response: retrospective analysis of survival after long-term follow-up. Leukemia Res. 2015 May;39(5):520–524.
   PubMed Web of Science ®Google Scholar
• Thepot S, Itzykson R, Seegers V, et al. Azacitidine in untreated acute myeloid leukemia: a report on 149 patients. Am J Hematol. 2014 Apr;89(4):410–416.
   PubMed Web of Science ®Google Scholar
• Prebet T, Gore SD, Thepot S, et al. Outcome of acute myeloid leukaemia following myelodysplastic syndrome after azacitidine treatment failure. Br J Haematol. 2012 Jun;157(6):764–766.
   PubMed Web of Science ®Google Scholar
• Montalban-Bravo G, Huang X, Naqvi K, et al. A clinical trial for patients with acute myeloid leukemia or myelodysplastic syndromes not eligible for standard clinical trials. Leukemia. 2017 Jul;31(7):1659.
   PubMed Web of Science ®Google Scholar
• Jung HA, Maeng CH, Kim M, et al. Platelet response during the second cycle of decitabine treatment predicts response and survival for myelodysplastic syndrome patients. Oncotarget. 2015 Jun 30;6(18):16653–16662.
   PubMedGoogle Scholar
• Bernal T, Martinez-Camblor P, Sanchez-Garcia J, et al. Effectiveness of azacitidine in unselected high-risk myelodysplastic syndromes: results from the Spanish registry. Leukemia. 2015 Sep;29(9):1875–1881.
   PubMed Web of Science ®Google Scholar
• Vire E, Brenner C, Deplus R, et al. The polycomb group protein EZH2 directly controls DNA methylation. Nature. 2006 Feb 16;439(7078):871–874.
   PubMed Web of Science ®Google Scholar
• Tobiasson M, McLornan DP, Karimi M, et al. Mutations in histone modulators are associated with prolonged survival during azacitidine therapy. Oncotarget. 2016 Apr 19;7(16):22103–22115.
   PubMedGoogle Scholar
• Bullinger L, Dohner K, Dohner H. Genomics of acute myeloid leukemia diagnosis and pathways. J Clin Oncol. 2017 Mar 20;35(9):934–946.
   PubMed Web of Science ®Google Scholar
• Coombs CC, Sallman DA, Devlin SM, et al. Mutational correlates of response to hypomethylating agent therapy in acute myeloid leukemia. Haematologica. 2016 Nov;101(11):e457–e460.
   PubMed Web of Science ®Google Scholar
• Hiller JK, Schmoor C, Gaidzik VI, et al. Evaluating the impact of genetic and epigenetic aberrations on survival and response in acute myeloid leukemia patients receiving epigenetic therapy. Ann Hematol. 2017 Apr;96(4):559–565.
   PubMed Web of Science ®Google Scholar
• Itzykson R, Kosmider O, Cluzeau T, et al. Impact of TET2 mutations on response rate to azacitidine in myelodysplastic syndromes and low blast count acute myeloid leukemias. Leukemia. 2011 Jul;25(7):1147–1152.
   PubMed Web of Science ®Google Scholar
• Bejar R, Lord A, Stevenson K, et al. TET2 mutations predict response to hypomethylating agents in myelodysplastic syndrome patients. Blood. 2014 Oct 23;124(17):2705–2712.
   PubMed Web of Science ®Google Scholar
• Traina F, Visconte V, Elson P, et al. Impact of molecular mutations on treatment response to DNMT inhibitors in myelodysplasia and related neoplasms. Leukemia. 2014 Jan;28(1):78–87.
   PubMed Web of Science ®Google Scholar
• Takahashi K, Patel K, Bueso-Ramos C, et al. Clinical implications of TP53 mutations in myelodysplastic syndromes treated with hypomethylating agents. Oncotarget. 2016 Mar 22;7(12):14172–14187.
   PubMedGoogle Scholar
• Huang Y, Anderle P, Bussey KJ, et al. Membrane transporters and channels: role of the transportome in cancer chemosensitivity and chemoresistance. Cancer Res. 2004 Jun 15;64(12):4294–4301.
   PubMed Web of Science ®Google Scholar
• Raynal NJ, Momparler LF, Rivard GE, et al. 3-Deazauridine enhances the antileukemic action of 5-aza-2ʹ-deoxycytidine and targets drug-resistance due to deficiency in deoxycytidine kinase. Leuk Res. 2011 Jan;35(1):110–118.
   PubMed Web of Science ®Google Scholar
• Mahfouz RZ, Jankowska A, Ebrahem Q, et al. Increased CDA expression/activity in males contributes to decreased cytidine analog half-life and likely contributes to worse outcomes with 5-azacytidine or decitabine therapy. Clin Cancer Res. 2013 Feb 15;19(4):938–948.
   PubMed Web of Science ®Google Scholar
• Shen L, Kantarjian H, Guo Y, et al. DNA methylation predicts survival and response to therapy in patients with myelodysplastic syndromes. J Clin Oncol. 2010 Feb 1;28(4):605–613.
   PubMed Web of Science ®Google Scholar
• Fandy TE, Herman JG, Kerns P, et al. Early epigenetic changes and DNA damage do not predict clinical response in an overlapping schedule of 5-azacytidine and entinostat in patients with myeloid malignancies. Blood. 2009 Sep 24;114(13):2764–2773.
   PubMed Web of Science ®Google Scholar
• Klco JM, Spencer DH, Lamprecht TL, et al. Genomic impact of transient low-dose decitabine treatment on primary AML cells. Blood. 2013 Feb 28;121(9):1633–1643.
   PubMed Web of Science ®Google Scholar
• Ettou S, Audureau E, Humbrecht C, et al. Fas expression at diagnosis as a biomarker of azacitidine activity in high-risk MDS and secondary AML. Leukemia. 2012 Oct;26(10):2297–2299.
   PubMed Web of Science ®Google Scholar
• Bohl SR, Dolnik A, Jensen T, et al. Gene expression analysis of decitabine treated AML: high impact of tumor suppressor gene expression changes. Leuk Lymphoma. 2017 Sep;58(9):1–4.
   PubMed Web of Science ®Google Scholar
• Yun H, Damm F, Yap D, et al. Impact of MLL5 expression on decitabine efficacy and DNA methylation in acute myeloid leukemia. Haematologica. 2014 Sep;99(9):1456–1464.
   PubMed Web of Science ®Google Scholar
• Mims A, Walker AR, Huang X, et al. Increased anti-leukemic activity of decitabine via AR-42-induced upregulation of miR-29b: a novel epigenetic-targeting approach in acute myeloid leukemia. Leukemia. 2013 Apr;27(4):871–878.
   PubMed Web of Science ®Google Scholar
• Braun T, Itzykson R, Renneville A, et al. Molecular predictors of response to decitabine in advanced chronic myelomonocytic leukemia: a phase 2 trial. Blood. 2011 Oct 6;118(14):3824–3831.
   PubMed Web of Science ®Google Scholar
• Cluzeau T, Robert G, Mounier N, et al. BCL2L10 is a predictive factor for resistance to azacitidine in MDS and AML patients. Oncotarget. 2012 Apr;3(4):490–501.
   PubMedGoogle Scholar
• Craddock C, Quek L, Goardon N, et al. Azacitidine fails to eradicate leukemic stem/progenitor cell populations in patients with acute myeloid leukemia and myelodysplasia. Leukemia. 2013 Apr;27(5):1028–1036.
   PubMed Web of Science ®Google Scholar
• Jung N, Dai B, Gentles AJ, et al. An LSC epigenetic signature is largely mutation independent and implicates the HOXA cluster in AML pathogenesis. Nat Commun. 2015 Oct;7(6):8489.
   Google Scholar
• Prebet T, Sun Z, Figueroa ME, et al. Prolonged administration of azacitidine with or without entinostat for myelodysplastic syndrome and acute myeloid leukemia with myelodysplasia-related changes: results of the US Leukemia Intergroup trial E1905. J Clin Oncol. 2014 Apr 20;32(12):1242–1248.
   PubMed Web of Science ®Google Scholar
• Uy GL, Duncavage EJ, Chang GS, et al. Dynamic changes in the clonal structure of MDS and AML in response to epigenetic therapy. Leukemia. 2017 Apr;31(4):872–881.
   PubMed Web of Science ®Google Scholar
• Lübbert M, Grishina O, Schmoor C, et al. Results of the randomized phase II study decider (AMLSG 14-09) comparing decitabine (DAC) with or without valproic acid (VPA) and with or without all-trans retinoic acid (ATRA) add-on in newly diagnosed elderly non-fit AML patients. Blood. 2016;128(22):589–590.
   Web of Science ®Google Scholar
• Blum W, Schwind S, Tarighat SS, et al. Clinical and pharmacodynamic activity of bortezomib and decitabine in acute myeloid leukemia. Blood. 2012 Jun 21;119(25):6025–6031.
   PubMed Web of Science ®Google Scholar
• Vasu S, He S. Decitabine enhances anti-CD33 monoclonal antibody BI 836858-mediated natural killer ADCC against AML blasts. Blood. 2016 Jun 9;127(23):2879–2889.
   Google Scholar
• Fathi AT, Erba HP, Lancet JE, et al. Vadastuximab talirine plus hypomethylating agents: a well-tolerated regimen with high remission rate in frontline older patients with acute myeloid leukemia (AML). Blood. 2016;128(22):591–592.
   Web of Science ®Google Scholar
• Yang H, Bueso-Ramos C, DiNardo C, et al. Expression of PD-L1, PD-L2, PD-1 and CTLA4 in myelodysplastic syndromes is enhanced by treatment with hypomethylating agents. Leukemia. 2014 Jun;28(6):1280–1288.
   PubMed Web of Science ®Google Scholar
• Jilg S, Reidel V, Muller-Thomas C, et al. Blockade of BCL-2 proteins efficiently induces apoptosis in progenitor cells of high-risk myelodysplastic syndromes patients. Leukemia. 2016 Jan;30(1):112–123.
   PubMed Web of Science ®Google Scholar
• DiNardo CD, Pratz KW, Letai A, et al. Safety and preliminary efficacy of venetoclax with decitabine or azacitidine in elderly patients with previously untreated acute myeloid leukaemia: a non-randomised, open-label, phase 1b study. Lancet Oncol. 2018 Feb;19(2):216–228.
   PubMed Web of Science ®Google Scholar
• Goodyear O, Agathanggelou A, Novitzky-Basso I, et al. Induction of a CD8+ T-cell response to the MAGE cancer testis antigen by combined treatment with azacitidine and sodium valproate in patients with acute myeloid leukemia and myelodysplasia. Blood. 2010 Sep 16;116(11):1908–1918.
   PubMed Web of Science ®Google Scholar
• Platzbecker U, Wermke M, Radke J, et al. Azacitidine for treatment of imminent relapse in MDS or AML patients after allogeneic HSCT: results of the RELAZA trial. Leukemia. 2012 Mar;26(3):381–389.
   PubMed Web of Science ®Google Scholar